Semantic Scholar uses AI to extract papers important to this topic.
Questionable data and poor antibody performance may have a common factor: antigens "hitchhiking" on the very antibodies designed… Expand The prognosis for patients with malignant gliomas remains poor, and novel treatment paradigms are needed. Radioimmunotherapeutic… Expand Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL
Tumors contain both microscopic and macroscopic… Expand Introduction: Despite treatment advances for malignant gliomas in adults, prognosis remains poor, largely due to the infiltrative… Expand 2035 Background: GBM is the most common and clinically aggressive primary brain tumor. For recurrent GBM, treatment by surgical… Expand A key limitation in developing radiotherapeutic proteins is the expense of manufacturing the drug in small batches using… Expand 2039 Background: Interstitial 131I-chTNT-1/B MAb (Cotara) is a radioiodinated chimeric monoclonal antibody specific for DNA and… Expand Treatment of malignant glioma is therapeutically challenging. Despite improvements in neurosurgery, radiotherapy and chemotherapy… Expand The potential of human immunotherapeutics now revolutionizing modern cancer therapy has yet to make an impact in veterinary… Expand OBJECTIVE: We report the safety and feasibility of using convection-enhanced delivery to administer Cotara (Peregrine… Expand